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Diabetic retinopathy (DR) is a major cause of blindness in working age adults, and oxidative stress plays a vital role in the
pathogenesis of DR. Pigment-epithelium-derived factor (PEDF), a multifunctional protein, has shown to inhibit the development
ofDRbyaccumulatingevidence. ThispaperhighlightsthecurrentunderstandingofprobablemechanismabouthowPEDFblocks
the deterioration of DR through its antioxidative properties and application prospects of PEDF as a novel therapeutic target in DR.
Gene therapy of PEDF is becoming more and more acceptable and will widely be applied to the actual treatment in the near future.
1.Introduction
Diabetic retinopathy (DR) is the leading cause of acquired
vision loss among adults of working age in developed
countries worldwide and has been perceived as the most
common microvascular complications of diabetes [1–3].
Therefore, within three to ﬁve years after the onset of type
1 diabetes and shortly after the diagnosis of type 2 diabetes,
the diabetic patients are recommended to be screened for
retinopathy with an initial dilated and comprehensive eye
examination by an ophthalmologist regularly [4]. Chronic
hyperglycemia which is well documented is a primary
initiator of DR [5]. In principle, intensive glycemic control
can delay the development of DR [5]. However, it is
noteworthy that some patients may still develop DR even
with good glycemic control [6, 7]. This remaining eﬀect,
prior to glycemic control, suggests a “metabolic memory”
phenomenon. Furthermore, a growing number of studies
have shown that the retina experience increased oxidative
damage continuously, even in tight glycemic control, and
oxidative stress plays a vital role in the pathogenesis of DR
[6, 8].
The molecular mechanisms of hyperglycemia-induced
DR are not fully clear, and the majority of publications focus
on multiple biochemical pathways, including the augmenta-
tionofpolyolpathway[9],proteinkinaseC(PKC)activation
[10], increased advanced glycation endproducts (AGEs)
formation, the receptor for AGEs and its activating ligands
[11], and overactivity of the hexosamine pathway [12].
However, all the mechanisms are activated by a single event:
aberrant production of the mitochondria-derived reactive
oxygen species (ROS) to increase the level of oxidative stress
[13]. Therefore, antioxidant therapy is being studied to
prevent induction of the various pathogenic mechanisms
of DR. With the failure of demonstrating that dietary
supplementationsofmultiantioxidantshavebeneﬁcialeﬀects
clinically [14], an antioxidant which could speciﬁcally target
pathogenesis of DR is no time to delay. Pigment-epithelium-
derived factor (PEDF), a 50-kDa secreted glycoprotein,
recently is shown to inhibit the development of DR through
its antioxidative properties. This paper summarizes the
probable protective mechanism of PEDF in high-glucose-
induced oxidative stress and application prospects of PEDF
as a novel therapeutic target in DR.
2.PEDFand ItsPotentialProtectiveRole
of OxidativeStress inDiabeticRetinopathy
2.1. PEDF and Its Biological Function. PEDF is a 418-
aminoacid, 50-KDa protein which was ﬁrst puriﬁed from2 Journal of Biomedicine and Biotechnology
conditioned medium from both fetal and adult retinal pig-
ment epithelial (RPE) cells [15–18] and it is a noninhibitory
member of the serine protease inhibitor (serpin) family.
PEDF is widely expressing throughout the body, especially
in the nervous system and the retina. According to current
research, PEDF has shown that it is a multifunctional protein
with demonstrable neurotrophic [19, 20], antiangiogenic
[16], antivasopermeability [21], antiinﬂammatory [22],
antiﬁbrosis [23], and antitumorigenic [24] properties and
inhibited the development of DR through its antioxidative
properties by accumulating evidence [25–28].
Earlier clinical studies demonstrated an inverse correla-
tion of the levels of intraocular PEDF and the development
of abnormal angiogenesis in some ocular diseases, such
as proliferative diabetic retinopathy (PDR) [16, 29–32].
Similarly, in mouse model of type 2 diabetes mellitus, lower
vitreous or aqueous humour levels of PEDF are associated
with early phase of experimental DR [16, 31, 33], and
decreased protein levels of PEDF in the retina are associated
with ischemia-induced retinal neovascularization in the
oxygen-induced retinopathy (OIR) model as well [34].
Therefore, existing research data demonstrated that
upregulation or substitution of PEDF may be a promising
therapeutictargetforDR[16,25,35–37],especiallyoxidative
stress-involved retinal tissue damage [38]. Then, experimen-
tal interventions to increase locally PEDF concentrations,
either by an adenovirus expressing human PEDF or a
puriﬁedrecombinantPEDFprotein,haveshowntoattenuate
retinal tissue damage in diﬀerent animal models [22, 39].
Thus, ﬁnding a good way for controlling PEDF expression
and action in the retina has become a research focus.
In addition, PEDF suppresses vascular endothelial
growth-factor-induced (VEGF-induced) retinal microvascu-
lar endothelial cell proliferation and migration [40]a n d
inhibits VEGF activation in human retinal endothelial cells
in vitro condition [41]. In contrast, PEDF has a synergistic
action with VEGF on cell proliferation in endothelial cells
cultured in the presence of VEGF [42]. Moreover, the VEGF
and PEDF expression in M¨ uller cells is unbalanced under
high-glucose concentration, which contributes to retinal
neovascularization in DR [43]. Since VEGF plays a pivotal
role in the formation of ROS, to deﬁning the speciﬁc eﬀects
of PEDF, high-glucose-induced oxidative stress will also be
important.
2.2. Antioxidative Properties of PEDF in Diabetic Retinopathy
2.2.1. Inhibit AGEs-Induced Injury. AGEs, senescent macro-
proteins formed at an accelerated rate in diabetes, cause
apoptotic cell death in retinal pericytes [44, 45]. Studies
have found AGEs signiﬁcantly decreased endothelial mRNA
levels of PEDF in endothelial cells [46], and PEDF proteins
protect cultured retinal pericytes from AGEs-induced injury
probably via oxidative stress generation [25]. Thus, we will
introduce the diﬀerent possible mechanisms of PEDF to
inhibit AGEs-induced injury in DR.
Retinal Pericytes. Earlier studies have found that loss of
pericytes and increased vascular permeability, followed by
microvascular occlusion in the retinas, ultimately leaded
to the development of DR [47, 48]. Experimental analysis
revealed that pericytes possessed of a membrane protein
with binding aﬃnity for PEDF which signiﬁcantly inhib-
ited AGEs-induced ROS generation and the subsequent
decrease in DNA synthesis and apoptotic cell death in
pericytes. Furthermore, PEDF proteins completely restored
the downregulation of bcl-2 (an antiapoptotic molecule)
gene expressing in AGEs-exposed pericytes [25]. Similarly,
thestudieshavedemonstratedthatPEDFcompletelyblocked
high-glucose-orH2O2-inducedintracellularROSgeneration
and an increased ratio of bax to bcl-2 mRNA level with
subsequent activation of caspase-3 in pericytes [49]. In
addition, PEDF protected high glucose- (30mM) or H2O2-
induced pericyte apoptosis and dysfunction through its
antioxidative properties via glutathione peroxidase (GPx)
induction. Simultaneously, the study also found that PEDF’s
mRNAlevelsthemselvesweredownregulatedinhigh-glucose
(HG-) or H2O2-exposed pericytes.
These results all demonstrated that PEDF proteins pro-
tected cultured pericytes from AGEs-induced cytotoxicity
through its antioxidative properties, and substitution of
PEDF proteins may be a promising strategy in treatment of
patients with DR.
Monocyte Chemoattractant Protein-1 (MCP-1). Further
work have shown that PEDF prevented the AGEs-induced
upregulation of monocyte chemoattractant protein-1
(MCP-1) mRNA contents as well as protein production in
microvascular endothelial cells (ECs) [50]. Moreover, levels
of MCP-1 in vitreous ﬂuids have been correlated with the
severity of PDR [51].
Rage. There is a growing body of evidence that RAGE is a
signal-transducing receptor for AGEs, and that engagement
of RAGE by AGEs elicits vascular inﬂammation and alters
gene expression in retinal vascular wall cells, thereby it is
involved in the development and progression of DR [45, 50,
52–54]. Recent studies have shown that PEDF could inhibit
diabetes- (in the eye of diabetic rats) or AGEs-induced (in
vitro) RAGE gene expression by blocking the superoxide-
mediated NF-kappaB activation [36].
Endothelial NO Synthase (eNOS). Studies have shown that
PEDF prevented the AGEs-elicited endothelial NO synthase
(eNOS) reduction through its antioxidative properties in
AGEs-exposed human umbilical vein ECs (HUVECs) [55].
Andendothelialdysfunctionduetoreducedsynthesisand/or
bioavailability of nitric oxide (NO) is an initial step of
atherosclerotic vascular disease in diabetes [56–58].
Platelet Activation and Aggregation. T h e r ei sa c c u m u l a t i n g
evidence that the oxidative stress generation is involved in
platelet activation and aggregation [59, 60]. These observa-
tions suggest that the inhibition of platelet activation and
aggregation may be a novel therapeutic target for preventing
the development and progression of vascular complications
in patients with diabetes. Further, the researchers have foundJournal of Biomedicine and Biotechnology 3
that PEDF prevented platelet activation and aggregation in
diabetic rats or AGEs-injected rats through its antioxidative
properties by suppressing NADPH oxidase-driven superox-
ide generation, deleterious eﬀects of AGEs [61].
The Src Pathway. PEDF inhibited AGEs-induced ROS gener-
ation by increasing levels of SOD and GSH and also blocked
the activation of caspase-3. Furthermore, PEDF induced cell
survival via the Src pathway by Src phosphorylation at Y419,
as evidenced by a pharmacological inhibitor and Src mutants
[62].
Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway. Recent
studies demonstrated that PEDF could inhibit the AGEs-
BSA-induced permeability via phosphatidylinositol 3-kinase
(PI3K)/Akt pathway. AGEs-BSA increased the ECs perme-
ability by stimulating ROS generation via NADPH oxidase
activity and Akt phosphorylation at Ser473. PEDF decreased
ROS generation in AGEs-BSA-exposed endothelial cells by
suppressing the NADPH oxidase activity via downregu-
lating the phosphorylation of p22PHOX at Thr147. This
led to blockade of AGEs induction of PI3K/Akt activation
in permeability. Furthermore, PEDF inhibited the AGEs-
BSA-induced permeability by increased expression of tight
junction protein zona occludens-1 (ZO-1), coincident with
an increase in barrier properties of endothelial monolayer
[63].
2.2.2. Inhibit Leptin-Induced Injury. PEDF was found to
inhibit the leptin-induced ROS generation and upregulation
of VEGF mRNA levels including any increase in DNA
synthesis in microvascular ECs [64]. Indeed, leptin levels in
vitreous were correlated with PDR [65].
2.2.3. Inhibit Tumor Necrosis Factor-α (TNF-α-) Induced
Injury. The studies demonstrated that PEDF inhibited
tumor necrosis factor-α (TNF-α-) induced redox-sensitive
transcriptional factor NF-kappaB activation and subsequent
interleukin IL-6 overexpression at both mRNA and protein
levels in human umbilical vein endothelial cell (HUVEC)
by suppressing NADPH oxidase-mediated ROS generation
[66]. In addition, TNF-alpha which is initially involved in
the pathogenesis of atherosclerosis [67, 68] and the classic
proinﬂammatory cytokines, downregulated PEDF mRNA
levels [66].
2.2.4. Inhibit Angiopoietin-II (Ang II-) Induced Injury. The
researchers have found that Angiopoietin-II (Ang II) signiﬁ-
cantly induced NF-kappaB activation and subsequent MCP-
1 expression in HUVEC, both of which were completely
inhibited by PEDF. Subsequently, PEDF inhibited Ang-II-
induced upregulation of mRNA levels of p22PHOX,N o x 4 ,
and gp91PHOX/Nox2, which are membrane components of
NADPH oxidase and its enzymatic activity in HUVEC [69].
Another study found that Ang II also signiﬁcantly decreased
PEDF mRNA levels in ECs, which was completely reversed
by an Ang II type 1 receptor blocker, telmisartan [70]. Fur-
thermore, anti-PEDF Ab signiﬁcantly inhibited the growth-
stimulating eﬀects of cocultured ECs on pericytes. These
results demonstrated that PEDF, an EC-derived mitogen or
survivalfactorforretinalpericytes,inhibitedAng-II-induced
ECs activation by suppressing NADPH-oxidase-mediated
ROSgeneration,andsuppressionbyAngIIoftheEC-derived
PEDFmaybeinvolvedinexacerbationofDRinpatientswith
hypertension. In addition, PEDF was found to completely
inhibit high-glucose- or H2O2-induced increase in a mRNA
ratio of Ang II to Angiopoietin-I (Ang I) and upregulation
of VEGF mRNA levels in pericytes. VEGF and angiopoietin
(Ang) have been known that they were the major regulators
of vascular integrity and involved in DR as well [71].
2.2.5. Inhibit HOL-LDL-Induced Injury. PEDF ameliorated
HOL-LDL-induced MCP-1 and the subsequent NF-kappaB
activation eﬀectively. Moreover, PEDF signiﬁcantly amelio-
rated HOG-LDL-induced ROS generation through upregu-
lation of superoxide dismutase 1 expression [72]. This study
represented a new mechanism for the salutary eﬀect of PEDF
in DR.
2.2.6. Inhibit High-Glucose (HG)-Induced JAK2/STAT3 Acti-
vation. A recent report suggested that ACEI exerted a
protective eﬀe c to nD R ,a n dt h i sp r o t e c t i v ee ﬀect could
be reﬂected by a decreased VEGF-to-PEDF ratio, which is
a result of reduced mitochondrial ROS production itselfs
caused by ACEI-induced increase of proliferator-activated
receptor gamma (PPARγ) and subsequent upregulation of
uncoupling protein-2 (UCP-2) expression [73]. Further
work in vitro has demonstrated that PEDF could decrease
mitochondria-derived ROS generation and subsequently
downregulate VEGF expression, possibly through inhibiting
HG-inducedJAK2/STAT3activation[74].Thesestudiespave
a new way for future in treatment of DR.
2.2.7. Regulation of PEDF Expression In Vivo. PEDF levels
in aqueous humor or vitreous were associated with total
antioxidant capacity in humans [38, 75] and suggested that
PEDF may act as an endogenous antioxidant in the eye and
upregulation or substitution of PEDF may be a therapeutic
target for oxidative stress-involved eye diseases, especially
PDR.
Retinal PEDF levels were reduced in diabetic rat, which
were restored by PEDF injections. Decreased amplitudes of
a- and b-wave in the ERG in diabetic rats, which were in
parallel with GFAP overexpression in the M¨ uller cells, also
could be blocked by PEDF injections. Further, retinal 8-
OHdG, p22PHOX, VEGF levels, and NADPH oxidase activity
were increased, and BRB was broken in diabetic rats, both of
which were ameliorated by the treatment of PEDF [26].
In addition, studies with rats, intravenous administra-
tion of AGEs, and simultaneous treatments with PEDF
demonstratedthatPEDFdecreasedROSgenerationinAGEs-
exposed endothelial cells by suppressing NADPH oxidase
activity via downregulation of mRNA levels of p22PHOX
and gp91PHOX and inhibited the AGEs-induced vascular4 Journal of Biomedicine and Biotechnology
hyperpermeability, the characteristic feature of early DR, by
suppressing VEGF expression [76].
Furthermore, the action of PEDF not only varied with
the cell type but also depended on its concentration and
environmental conditions [77].
3. Application Prospectsof PEDFin
DiabeticRetinopathy
Large prospective clinical studies have shown that intensive
blood glucose control reduced the incidence and progression
of DR [5, 48]. However, strict control of hyperglycemia
is often diﬃcult to maintain and may increase the risk
of severe hypoglycemia in diabetic patients. In addition,
photocoagulationandvitrectomy,currentconventionalther-
apeutic options for the treatment of PDR, are limited
by considerable side eﬀects. Therefore, developing novel
therapeutic strategies that speciﬁcally target pathogenesis of
DR is desired for patients with diabetes. Based on the above
role and regulation mechanism of PEDF in DR, the research
on the treatment of PDR has turned to the regulation of
angiogenesis inhibitors and growth factors.
3.1. Current and Potential Molecular Therapie of PEDF
3.1.1.PEDFandPEDF-DerivedPeptide. Themultifunctional
PEDF, more eﬀective than other antiangiogenic factors, is
a good candidate for treatment of DR. Because a large
part of endogenous PEDF-binding aﬃnity to extracellular
matrix components and cell-surface receptors, it would not
achieve a protective eﬀect. However, injection of exogenous
PEDF, competitive binding of PEDF in the extracellular
binding sites, will release PEDF from extracellular matrix
and subsequently achieve therapeutic concentrations. The
problems of current stage are as follow: (1) PEDF is a 50-kDa
protein, and its structural features limit practical application
as pharmaceuticals; (2) underestimated the carrier itself
could induce the inﬂammatory response; (3) currently there
is no good control methods for PEDF which has secreted
into the extracellular. However, many biologically active
fragment of PEDF has been known, and if we can ﬁnd
the active fragment, equivalent or near equivalent with
PEDF, which is replaced with small peptides, we will avoid
or reduce the inﬂammatory reaction by virus or other
carriers through slow release of directly permeating sclera or
intravitreal injection [78]. A recent study demonstrated that
an antiangiogenic peptide, PEDF-34, reduced circulating
endothelial cells during ischemia-induced neovasculariza-
tion [79]. Thus, the PEDF-34 peptide could be a superior
biological therapeutic for the treatment of PDR and has
great potential for large-scale pharmaceutical development.
A disadvantage, however, of using small peptide derivatives
is that they tend to be cleared rapidly from tissues and thus
may be less eﬀective therapeutically unless they are protected
from rapid enzymatic degradation and tissue clearance.
3.1.2. Biodegradable Nanospheres. Nanospheres, biocompat-
ible, biodegradable, and producer of fewer side eﬀects,
is one way to avoid disadvantage of peptide. Moreover,
there is abundant experimental evidence that intravitreal
injections of drugs encapsulated in PLGA-poly (lactide-co-
glycolide) nanospheres are both useful and eﬀective [80, 81].
A recent study has found that delivering PEDF82−121,af r e e
peptide,inPLGAnanospheresisaneﬀectivewayofachieving
controlled release of therapeutically active levels of the
peptide [82]. Such delivery systems can be manipulated to
provide controlled release of physiological levels of bioactive
products for both short- and long-term needs [83].
3.1.3. Gene Therapy. Gene therapy involves the replacement
of a faulty gene or the insertion of a new gene. Treatment
of angiogenic disease can be achieved by the insertion of
genes that encode antiangiogenic proteins, including the
vitreous body and subretinal injection. Adenovirus and
adeno-associated virus (AAV) has shown particular promise
in the delivery of antiangiogenic DNA. The ﬁrst human trial
of recombinant PEDF introduced via the adenoviral vector
AdPEDF.11 suggested that intravitreal delivery is relatively
well tolerated with the antiangiogenic eﬀect of PEDF per-
sisting for several months [84]. PEDF transgenic (PEDF-Tg)
mice that ubiquitously express human PEDF driven by the
β-actinpromoterinhibited neovasculardisorderssuchasDR
[85]. These results have provided valuable information with
regards to gene therapy for the treatment of DR.
4. Conclusion
PEDF, a multifunctional factor, has shown to inhibit the
development of DR by accumulating evidence. This paper
highlightsthecurrentunderstandingofprobablemechanism
about how PEDF blocks the deterioration of DR through
its antioxidative properties and application prospects of
PEDF as a novel therapeutic target in DR. Gene therapy is
becoming more and more acceptable and widely applied to
the actual treatment. PEDF and its fragments, transferred
into virus vector or made of biodegradable implant for
localinjection,havebroadapplicationprospectsintreatment
of DR. However, the drug screening and selection of the
best way to enter the human body need large number of
researches.
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